Pfizer, Merck Beat Estimates on Eliquis, Keytruda Strength

Pfizer reported second quarter earnings that exceeded analyst projections, prompting the company to lift the lower end of its full year revenue forecast while trimming expectations for its Covid related offerings. The results reflect a pharmaceutical sector adjusting to post pandemic realities where demand for emergency products has faded and established medicines drive performance.

The company now projects full year revenue between 60.5 billion and 62.5 billion dollars, compared with its prior range of 59.5 billion to 62.5 billion. This adjustment incorporates an additional 1.5 billion dollars in anticipated sales from non Covid products. Revenue for Covid vaccine and Paxlovid combined was revised downward to 4 billion dollars from an earlier estimate near 5 billion.

Second quarter revenue reached 15.03 billion dollars, surpassing the 14.41 billion dollar consensus and rising 3 percent from the prior year. Adjusted earnings per share came in at 77 cents, ahead of the 68 cents expected. The firm maintained its full year adjusted profit guidance of 2.80 to 3 dollars per share.

Sales of the blood thinner Eliquis climbed 19 percent to 2.43 billion dollars, well above the 2.08 billion dollar estimate. The targeted cancer therapy Padcev also contributed positively. These gains helped offset continued weakness in the Covid portfolio, which no longer benefits from the extraordinary conditions of the pandemic era.

Pfizer recorded a net loss of 248 million dollars for the quarter, or 4 cents per share, contrasting with net income of 2.91 billion dollars, or 51 cents per share, in the same period last year. Shares rose 1.8 percent in premarket trading following the release.

The pattern at Pfizer aligns with broader industry trends where companies navigate the withdrawal of government backed demand for specific treatments. Investors continue to monitor progress on newer pipelines, including obesity related assets from the recent Metsera acquisition, as the firm seeks sustainable growth beyond 2028. Historical reliance on a narrow set of aging blockbusters has proven vulnerable to patent expirations and shifting medical needs, underscoring the value of diversified research and development efforts responsive to market signals rather than temporary policy priorities.

In a separate development the same day, Merck posted quarterly revenue of 16.61 billion dollars, exceeding expectations on the continued performance of Keytruda, which generated 8.37 billion dollars. That result similarly illustrates how leading therapies can sustain momentum when patient and physician demand remains steady, independent of external subsidies. Merck raised its full year revenue outlook accordingly.

Pharmaceutical results overall demonstrate that private sector innovation continues to deliver measurable outcomes even as one time revenue streams recede. Companies that adapt by emphasizing products with durable clinical utility tend to stabilize their financial positions more effectively than those tethered to episodic public health campaigns.